GIP Receptor Agonist Polypeptides for Diabetes and Bone Disorders
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for type-2 diabetes and bone disorders, such as bisphosphonates and GLP-1 mimetics, are inadequate in addressing defective insulin secretory responses and bone fragility fractures, with a need for novel approaches that target incretin hormones like GIP for effective insulin secretion and bone metabolism regulation.
Innovation Solution
Development of specific polypeptides, including those with the amino acid sequences HPXXPWIL and MLTKFETKSARVKGLSF, and their analogues, which act as GIP receptor agonists to enhance insulin secretion, bone formation, and reduce bone fragility, potentially used in pharmaceutical compositions for treating diabetes and bone disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stability of the object's composition
If bisphosphonates are used for treating bone disorders, then bone mass deterioration is reduced, but bone reconstruction does not occur
Solution Approach 1:
The patent uses GIP receptor agonists as intermediary substances that mediate between the existing bone metabolism pathways and the desired anabolic effect. These agonists activate GIP receptors on osteoblasts and osteoclasts, triggering intracellular signaling cascades (cAMP/PKA pathway) that promote bone formation and inhibit resorption, thereby serving as a mediator to achieve bone reconstruction that bisphosphonates cannot provide.
Solution Approach 2:
The patent changes the biochemical parameters of bone metabolism by introducing GIP receptor agonists that alter the signaling pathways in bone cells. Specifically, it changes the cAMP levels and downstream phosphorylation events in osteoblasts and osteoclasts, transforming the bone metabolism from a state of inhibition (bisphosphonate effect) to a state of active formation and regulated resorption.
2Productivity
If standalone GIP-based drugs are used, then insulin secretion should be enhanced, but effective insulin secretion does not occur in type-2 diabetes
Solution Approach 1:
The patent employs composite peptide structures that combine GIP-like sequences with specific modifications (amino acid substitutions, deletions, or additions) to create molecules that possess both GIP receptor agonist activity and improved stability or potency. These composite structures maintain the core bioactive sequence while incorporating elements that enhance therapeutic reliability in diabetic conditions.
Solution Approach 2:
The patent applies local quality modifications to the GIP peptide structure by making specific amino acid changes at particular positions (e.g., substitutions at positions 2, 8, or deletions of specific residues) to optimize receptor binding affinity and signaling efficiency while maintaining overall structural integrity. This localized optimization ensures reliable insulin secretion enhancement without requiring complete structural redesign.
3Productivity
If GLP-1 mimetics are used for diabetes treatment, then insulin secretion is improved, but bone fragility fractures are not addressed
Solution Approach 1:
The patent develops GIP receptor agonists with multi-functional capabilities: they stimulate insulin secretion from pancreatic beta cells (metabolic function) and simultaneously activate bone remodeling pathways in osteoblasts and osteoclasts (skeletal function). This universality allows a single agent to address both diabetes and bone fragility, overcoming the limitation of GLP-1 mimetics that lack significant bone-protective effects.
Data Source
AI summary
The present invention relates to polypeptides and analogues thereof for use in the treatment of diabetes and bone disorders. Also disclosed are pharmaceutical compositions comprising the polypeptides and analogues thereof, and methods for the treatment of diabetes and bone disorders.